Maria J Valkema1, Berend J van der Wilk2, Ben M Eyck2, Bas P L Wijnhoven2, Manon C W Spaander3, Michail Doukas4, Sjoerd M Lagarde2, Wendy M J Schreurs5, Mark J Roef6, J Jan B van Lanschot2, Roelf Valkema7. 1. Department of Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands m.valkema@erasmusmc.nl. 2. Department of Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands. 3. Department of Gastroenterology, Erasmus University Medical Center, Rotterdam, The Netherlands. 4. Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands. 5. Department of Nuclear Medicine, Zuyderland Medical Center, Heerlen, The Netherlands. 6. Department of Nuclear Medicine, Catharina Hospital Eindhoven, Eindhoven, The Netherlands; and. 7. Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands m.valkema@erasmusmc.nl.
Abstract
Active surveillance for patients with esophageal cancer and a clinically complete response (cCR) after neoadjuvant chemoradiotherapy (nCRT) is being studied. Active surveillance requires accurate clinical response evaluations. 18F-FDG PET/CT might be able to detect local tumor recurrence after nCRT as soon as the esophagus recovers from radiation-induced esophagitis. The aims of this study were to assess the value of serial 18F-FDG PET/CT scans for detecting local recurrence in patients beyond 3 mo after nCRT and to determine when radiation-induced esophagitis has resolved. Methods: This retrospective multicenter study included patients who had cCR after nCRT, who initially declined surgery, and who subsequently underwent active surveillance. Clinical response evaluations included 18F-FDG PET/CT, endoscopic biopsies, and endoscopic ultrasound with fine-needle aspiration at regular intervals. SUVmax normalized for lean body mass (SULmax) was measured at the primary tumor site. The percentage change in SULmax (Δ%SULmax) between the last follow-up scan and the scan at 3 mo after nCRT was calculated. Tumor recurrence was defined as biopsy-proven vital tumor at the initial tumor site. Results: Of 41 eligible patients, 24 patients had recurrent disease at a median of 6.5 mo after nCRT and 17 patients remained cancer free during a median follow-up of 24 mo after nCRT. Five of 24 patients with tumor recurrence had sudden intense SULmax increases of greater than 180%. In 19 of 24 patients with tumor recurrence, SULmax gradually increased (median Δ%SULmax, +18%), whereas SULmax decreased (median Δ%SULmax, -12%) in patients with ongoing cCR (P < 0.001, independent-samples t test). In patients with ongoing cCR, SULmax was lowest at 11 mo after nCRT. Conclusion: Serial 18F-FDG PET/CT might be a useful tool for detecting tumor recurrence during active surveillance. In patients with ongoing cCR, the lowest SULmax was reached at 11 mo after nCRT, suggesting that radiation-induced esophagitis had mostly resolved by that time. These findings warrant further evaluation in a larger cohort.
Active surveillance for patients with esophageal cancer and a clinically complete response (cCR) after neoadjuvant chemoradiotherapy (nCRT) is being studied. Active surveillance requires accurate clinical response evaluations. 18F-FDG PET/CT might be able to detect local tumor recurrence after nCRT as soon as the esophagus recovers from radiation-induced esophagitis. The aims of this study were to assess the value of serial 18F-FDG PET/CT scans for detecting local recurrence in patients beyond 3 mo after nCRT and to determine when radiation-induced esophagitis has resolved. Methods: This retrospective multicenter study included patients who had cCR after nCRT, who initially declined surgery, and who subsequently underwent active surveillance. Clinical response evaluations included 18F-FDG PET/CT, endoscopic biopsies, and endoscopic ultrasound with fine-needle aspiration at regular intervals. SUVmax normalized for lean body mass (SULmax) was measured at the primary tumor site. The percentage change in SULmax (Δ%SULmax) between the last follow-up scan and the scan at 3 mo after nCRT was calculated. Tumor recurrence was defined as biopsy-proven vital tumor at the initial tumor site. Results: Of 41 eligible patients, 24 patients had recurrent disease at a median of 6.5 mo after nCRT and 17 patients remained cancer free during a median follow-up of 24 mo after nCRT. Five of 24 patients with tumor recurrence had sudden intense SULmax increases of greater than 180%. In 19 of 24 patients with tumor recurrence, SULmax gradually increased (median Δ%SULmax, +18%), whereas SULmax decreased (median Δ%SULmax, -12%) in patients with ongoing cCR (P < 0.001, independent-samples t test). In patients with ongoing cCR, SULmax was lowest at 11 mo after nCRT. Conclusion: Serial 18F-FDG PET/CT might be a useful tool for detecting tumor recurrence during active surveillance. In patients with ongoing cCR, the lowest SULmax was reached at 11 mo after nCRT, suggesting that radiation-induced esophagitis had mostly resolved by that time. These findings warrant further evaluation in a larger cohort.
Authors: Lucian R Chirieac; Stephen G Swisher; Jaffer A Ajani; Ritsuko R Komaki; Arlene M Correa; Jeffrey S Morris; Jack A Roth; Asif Rashid; Stanley R Hamilton; Tsung-Teh Wu Journal: Cancer Date: 2005-04-01 Impact factor: 6.860
Authors: Sophie E Heethuis; Lucas Goense; Peter S N van Rossum; Alicia S Borggreve; Stella Mook; Francine E M Voncken; Annemarieke Bartels-Rutten; Berthe M P Aleman; Richard van Hillegersberg; Jelle P Ruurda; Gert J Meijer; Jan J W Lagendijk; Astrid L H M W van Lier Journal: Acta Oncol Date: 2018-05-21 Impact factor: 4.089
Authors: B J Noordman; M G E Verdam; S M Lagarde; J Shapiro; M C C M Hulshof; M I van Berge Henegouwen; B P L Wijnhoven; G A P Nieuwenhuijzen; J J Bonenkamp; M A Cuesta; J Th M Plukker; E J Spillenaar Bilgen; E W Steyerberg; A van der Gaast; M A G Sprangers; J J B van Lanschot Journal: Ann Oncol Date: 2018-02-01 Impact factor: 32.976
Authors: Penny Fang; Benjamin C Musall; Jong Bum Son; Amy C Moreno; Brian P Hobbs; Brett W Carter; Bryan M Fellman; Osama Mawlawi; Jingfei Ma; Steven H Lin Journal: Int J Radiat Oncol Biol Phys Date: 2018-03-02 Impact factor: 7.038
Authors: Philip Cornford; Joaquim Bellmunt; Michel Bolla; Erik Briers; Maria De Santis; Tobias Gross; Ann M Henry; Steven Joniau; Thomas B Lam; Malcolm D Mason; Henk G van der Poel; Theo H van der Kwast; Olivier Rouvière; Thomas Wiegel; Nicolas Mottet Journal: Eur Urol Date: 2016-08-31 Impact factor: 20.096
Authors: Bo Jan Noordman; Manon C W Spaander; Roelf Valkema; Bas P L Wijnhoven; Mark I van Berge Henegouwen; Joël Shapiro; Katharina Biermann; Ate van der Gaast; Richard van Hillegersberg; Maarten C C M Hulshof; Kausilia K Krishnadath; Sjoerd M Lagarde; Grard A P Nieuwenhuijzen; Liekele E Oostenbrug; Peter D Siersema; Erik J Schoon; Meindert N Sosef; Ewout W Steyerberg; J Jan B van Lanschot Journal: Lancet Oncol Date: 2018-06-01 Impact factor: 41.316
Authors: Nicolas Aide; Charline Lasnon; Patrick Veit-Haibach; Terez Sera; Bernhard Sattler; Ronald Boellaard Journal: Eur J Nucl Med Mol Imaging Date: 2017-06-16 Impact factor: 9.236
Authors: Bo Jan Noordman; Bas P L Wijnhoven; Sjoerd M Lagarde; Jurjen J Boonstra; Peter Paul L O Coene; Jan Willem T Dekker; Michael Doukas; Ate van der Gaast; Joos Heisterkamp; Ewout A Kouwenhoven; Grard A P Nieuwenhuijzen; Jean-Pierre E N Pierie; Camiel Rosman; Johanna W van Sandick; Maurice J C van der Sangen; Meindert N Sosef; Manon C W Spaander; Roelf Valkema; Edwin S van der Zaag; Ewout W Steyerberg; J Jan B van Lanschot Journal: BMC Cancer Date: 2018-02-06 Impact factor: 4.430